logo-loader
viewMedexus Pharmaceuticals Inc

Medexus Pharmaceuticals will begin selling Treosulfan in Canada, and will soon look to the US

Medexus Pharmaceuticals Inc (CVE:MDP) (OTC:PDDPF) CEO Ken d’Entremont tells Proactive Investors that Health Canada has authorized the Montreal-based specialty pharma company to distribute Treosulfan through the special access program.

Treosulfana is a conditioning agent used before stem cell transplantation.

The company will look to bring Treosulfann to the US, according to d'Entremont.

Quick facts: Medexus Pharmaceuticals Inc

Price: 4.01 CAD

TSX-V:MDP
Market: TSX-V
Market Cap: $57.96 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medexus Pharmaceuticals Inc named herein, including the promotion by the Company of Medexus Pharmaceuticals Inc in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Medexus Expands US assets by acquiring Aptevo Bio Therapeutics

Medexus Pharmaceuticals (CVE: MDP-OTCQB: PDDPF) CEO Ken d’Entremont joined Proactive's Steve Darling in Toronto with news the company has acquired Aptevo BioTherapeutics LLC, which owns the worldwide rights to the commercial hematology asset, IXINITY, for up-front cash consideration of...

on 4/3/20

2 min read